Synthesis and evaluation of haloperidol ester prodrugs metabolically activated by human carboxylesterase

被引:13
作者
Takahashi, Masato [1 ]
Uehara, Tomoki [1 ]
Nonaka, Minori [1 ]
Minagawa, Yuka [1 ]
Yamazaki, Riona [1 ]
Haba, Masami [1 ]
Hosokawa, Masakiyo [1 ]
机构
[1] Chiba Inst Sci, Fac Pharm, 15-8 Shiomi Cho, Choshi, Chiba 2880025, Japan
关键词
Haloperidol; Prodrug; Carboxylesterase; Enol ester; Sustained release; HUMAN LIVER; BINDING; SPECIFICITY; HYDROLYSIS; DECANOATE; ISOZYMES; COCAINE; HEROIN; AGENT; RAT;
D O I
10.1016/j.ejps.2019.03.009
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Two types of haloperidol prodrugs in which a chemical modification was carried out on the hydroxyl group or carbonyl group were synthesized, and their metabolic activation abilities were evaluated in a human liver microsome (HLM) solution, a human small intestine microsome (HIM) solution and solutions of human recombinant carboxylesterases (hCESs). The metabolic activation rates of alcohol ester prodrugs in HLM solution were similar to those in hCES2 solution, and haloperidol pentanoate and haloperidol hexanoate showed high metabolic activation rates in the synthesized alcohol ester prodrugs. In addition, haloperidol acetate and haloperidol 2-methylbutanoate were hydrolyzed as slowly as haloperidol decanoate. The results suggested that haloperidol prodrugs with a small chain or a branched chain are useful as prodrugs for sustained release. The metabolic activation rate of the enol ester prodrug in HLM solution was similar to that in hCES1 solution, and the enol ester prodrug was found to behave differently from alcohol ester prodrugs, which were metabolically activated by hCES2.
引用
收藏
页码:125 / 131
页数:7
相关论文
共 28 条
[1]   Crystal structure of human carboxylesterase 1 complexed with the Alzheimer's drug tacrine: From binding promiscuity to selective inhibition [J].
Bencharit, S ;
Morton, CL ;
Hyatt, JL ;
Kuhn, P ;
Danks, MK ;
Potter, PM ;
Redinbo, MR .
CHEMISTRY & BIOLOGY, 2003, 10 (04) :341-349
[2]   HALOPERIDOL DECANOATE - A PRELIMINARY REVIEW OF ITS PHARMACODYNAMIC AND PHARMACOKINETIC PROPERTIES AND THERAPEUTIC USE IN PSYCHOSIS [J].
BERESFORD, R ;
WARD, A .
DRUGS, 1987, 33 (01) :31-49
[3]  
Brzezinski MR, 1997, DRUG METAB DISPOS, V25, P1089
[4]   PHARMACOKINETICS OF HALOPERIDOL [J].
FROEMMING, JS ;
LAM, YWF ;
JANN, MW ;
DAVIS, CM .
CLINICAL PHARMACOKINETICS, 1989, 17 (06) :396-423
[5]   The Emerging Role of Human Esterases [J].
Fukami, Tatsuki ;
Yokoi, Tsuyoshi .
DRUG METABOLISM AND PHARMACOKINETICS, 2012, 27 (05) :466-477
[6]   Lipophilic nalmefene prodrugs to achieve a one-month sustained release [J].
Gaekens, Tim ;
Guillaume, Michel ;
Borghys, Herman ;
De Zwart, Loeckie L. ;
de Vries, Ronald ;
Embrechts, Roger C. A. ;
Vermeulen, An ;
Megens, Anton A. H. P. ;
Leysen, Josee E. ;
Herdewijn, Piet ;
Annaert, Pieter P. ;
Atack, John R. .
JOURNAL OF CONTROLLED RELEASE, 2016, 232 :196-202
[7]   A novel PEG-haloperidol conjugate with a non-degradable linker shows the feasibility of using polymer-drug conjugates in a non-prodrug fashion [J].
Heath, Felicity ;
Newman, Amy ;
Clementi, Chiara ;
Pasut, Gianfranco ;
Lin, Hong ;
Stephens, Gary J. ;
Whalley, Benjamin J. ;
Osborn, Helen M. I. ;
Greco, Francesca .
POLYMER CHEMISTRY, 2016, 7 (47) :7204-7210
[8]   Microsuspension of fatty acid esters of entecavir for parenteral sustained delivery [J].
Ho, Myoung Jin ;
Lee, Dae Ro ;
Im, Sung Hyun ;
Yoon, Jeong A. ;
Shin, Chang Yong ;
Kim, Hyun Jung ;
Jang, Sun Woo ;
Choi, Young Wook ;
Han, Young Taek ;
Kang, Myung Joo .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2018, 543 (1-2) :52-59
[9]  
HOSOKAWA M, 1995, DRUG METAB DISPOS, V23, P1022